US patients can now get Ozempic for half price if they can pay cash

Novo Nordisk has set a direct-to-consumer price of $499 per month for Ozempic for US cash-paying patients, nearly halving its list price, available via its NovoCare Pharmacy and other channels. This strategic move responds to political pressure from President Trump to lower drug costs and aims to broaden access for self-pay patients. Furthermore, it addresses competition from compounding pharmacies selling unapproved versions of GLP-1s and follows similar price adjustments by rival Eli Lilly for its GLP-1 offerings.

Analysis

Novo Nordisk is strategically de-risking its GLP-1 franchise by halving the price of Ozempic to $499 per month for US cash-paying patients, a move that addresses multiple pressures. This action directly responds to political calls from figures like President Trump for lower drug costs, preemptively mitigating regulatory and headline risk. It also establishes competitive parity with rival Eli Lilly, which has already enacted similar price cuts for its GLP-1 offerings, indicating that intense price competition is now the norm in the self-pay segment. Furthermore, the strategy is a direct countermeasure to the sales erosion from compounding pharmacies, which the company cited as a headwind in its recent earnings call. By offering an affordable, manufacturer-guaranteed product through its NovoCare direct-to-consumer platform and partners like GoodRx, Novo Nordisk aims to recapture market share from these unregulated alternatives and expand its addressable market to patients previously priced out. While this reduces the revenue per prescription in the cash-pay channel from a list price near $1,000, the company is likely banking on increased sales volume and brand loyalty to offset the margin impact, a strategy reflected in the market's moderately positive sentiment.

Key Decisions for Investors

• For investors in Novo Nordisk, this pricing action is a necessary defensive maneuver to protect market share from both Eli Lilly and unregulated compounded drugs; focus should be on upcoming earnings to see if increased patient volume in the cash-pay channel offsets the lower per-unit revenue.
• The parallel pricing strategies from Novo Nordisk and Eli Lilly signal that the high-margin, cash-pay segment for GLP-1 drugs is now highly competitive, meaning investors should anticipate that future growth in this channel will be driven primarily by volume rather than premium pricing.
• Given the direct link to political pressure, investors must factor in sustained headline and regulatory risk for major pharmaceutical firms, as drug pricing is likely to remain a contentious issue that could lead to further margin erosion or policy interventions.